WO2023017072 - RISK PREDICTION MODEL FOR PROSTATE CANCER
National phase entry:
Publication Number
WO/2023/017072
Publication Date
16.02.2023
International Application No.
PCT/EP2022/072425
International Filing Date
10.08.2022
Title **
[English]
RISK PREDICTION MODEL FOR PROSTATE CANCER
[French]
MODÈLE DE PRÉDICTION DE RISQUE POUR LE CANCER DE LA PROSTATE
Applicants **
RANDOX LABORATORIES LTD
Inventors
FITZGERALD, Stephen Peter
RUDDOCK, Mark
LAMONT, John
MCKENNA, Declan
Priority Data
2111635.5
13.08.2021
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1878 | |
| EPO | Filing, Examination, Granting | 8143 | |
| Japan | Filing, Examination, Granting | 1961 | |
| South Korea | Filing, Examination, Granting | 1614 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,336
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Single markers lack both sensitivity and specificity to stratify risk of PCa in patients who present with elevated tPSA and abnormal DRE. The novel combination of serum markers identified in this study could be employed to help triage patients into 'low' and 'high' risk categories, allowing general practitioners (GPs) to improve management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.[French]
Des marqueurs uniques sont dépourvus à la fois de sensibilité et de spécificité pour stratifier le risque de cancer de la prostate chez des patients qui présentent un tPSA élevé et un DRE anormal. La nouvelle combinaison de marqueurs sériques identifiés dans cette étude pourrait être utilisée pour aider les patients au triage dans des catégories de risque'bas'et'haut ', ce qui permet aux praticiens généraux (GPs) d'améliorer la gestion de patients dans l'établissement de soins primaires et réduire potentiellement le nombre de recommandations pour des traitements inutiles, invasifs et coûteux.